Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. - Wikidata - wikimedia - TriplyDB

Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial.

Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial.

http://www.wikidata.org/entity/Q37022421

about

Interventions for fatigue in Parkinson's disease Side effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacology Emerging approaches in Parkinson's disease - adjunctive role of safinamide Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease Targeting chelatable iron as a therapeutic modality in Parkinson's disease.A pivotal role of FOS-mediated BECN1/Beclin 1 upregulation in dopamine D2 and D3 receptor agonist-induced autophagy activation.Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease.Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.Therapeutic prospects for Parkinson disease.Dopamine receptor agonists for Parkinson's disease.Movement disorders in 2013: diagnosing and treating PD-the earlier the better?Novel thiazole derivatives: a patent review (2008 - 2012. Part 2).Early versus delayed initiation of pharmacotherapy in Parkinson's disease.Assessment of disease progression and functional benefit in neurodegenerative disease: can we tell the difference?Safinamide for the treatment of Parkinson's disease.Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias.Rational drug discovery design approaches for treating Parkinson's disease.Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson's Disease.Modern treatment in Parkinson's disease, a personal approach.Advances in clinical trials for movement disorders.Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds.A systematic review and mixed treatment comparison of monotherapy in early Parkinson's disease: implications for Latin America.Therapeutic approaches in Parkinson's disease and related disorders.New and emerging medical therapies in Parkinson's disease.Comparison of the Performances of (18)F-FP-CIT Brain PET/MR and Simultaneous PET/CT: a Preliminary Study.The entangled ER-mitochondrial axis as a potential therapeutic strategy in neurodegeneration: A tangled duo unchained.Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study.Current and experimental treatments of Parkinson disease: A guide for neuroscientists.The MPTP Story.Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson's disease patients Do we need a new levodopa?Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.Pharmacotherapy and generic health-related quality of life in Parkinson's disease.Drp1/Fis1 interaction mediates mitochondrial dysfunction, bioenergetic failure and cognitive decline in Alzheimer's disease.ABCB1: is there a role in the drug treatment of Parkinson's disease?Statistical Models of Parkinson's Disease Progression: Predictive Validity in a 3-Year Follow-up.Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson's disease patients.Parkinson's disease: recent advances.Meta-analysis of the adverse events associated with extended-release versus standard immediate-release pramipexole in Parkinson disease

P2860

Q24186581-2F752E4F-67A2-441E-82BE-034E1C5E1ED5 Q26738349-32E7554C-1751-4756-A8C3-CDB4DA12E576 Q26740905-89590F5F-869C-4C5F-BF04-0AC59D34B3A8 Q26748711-54234281-CE3F-4355-BF48-7C362A2CB04A Q33768106-712D4F6C-8436-4FB2-878D-FE1797890912 Q36777200-7A0551CA-41C6-4BBA-8C16-161B5616B224 Q36925905-D7D17BC3-8F1C-4A17-B456-FDE2948058F5 Q37506492-8D5664E4-B339-4B86-BA6D-3906192DC0A8 Q38137889-8109F97E-74FE-4CCC-A632-6C890E3EF71A Q38169202-8F7757E0-165B-478F-AF7C-4669ED58F0AF Q38176182-8B88050C-913A-425C-84CD-6454BBC0E541 Q38205485-96CC1001-B089-44AC-BF65-85BEA4123D06 Q38206403-6B3563FA-2105-41A1-94E3-80C13E916334 Q38219475-2E80B3C0-F57A-4334-9AD3-B48DD70FF778 Q38258514-2D977604-56BA-40F5-B39F-ED0BD015FDBD Q38314257-6B69BCED-72C9-406A-BA28-C034A7148D58 Q38520864-52207F04-5C46-490B-B6E0-64942B30B1A4 Q38545359-138A3F34-3680-4C67-85E2-46F9F051C656 Q38570529-009DD673-24FF-493B-8465-357CB804C949 Q38573937-42890F80-8445-445B-AE09-CA03959BFDE6 Q38656262-21744047-4653-4D22-9D6A-AD48C26EBB6D Q38687026-58DEE539-C530-487E-A075-CF04AD6C5792 Q38691406-BAA4F571-AA83-4ADE-A809-0ECBF673932B Q38718194-6793B577-B36B-4AD7-AE87-BA4C6A9184BD Q38829876-985AC4C1-EABE-4142-99F5-4B3C519967E3 Q38841508-778515FD-4CC8-4188-8FBA-5940CFBAE098 Q38865983-B971F372-0AA6-4787-B8EA-65A8A0091DF0 Q38941557-5BB25178-B9D0-4FC3-BBCA-8D5C1E3CA707 Q41825283-17FC79BB-356A-4E1C-B0EB-0AFFCF2101AE Q42035690-F61BBE20-4F02-465E-85E9-822790B8CEDD Q42043001-98529C26-F71E-4D7D-A7F5-0DE88A5C0896 Q46354756-B548C3DF-41BA-4F5A-BADF-C9994A75EC69 Q47914989-CA829CAC-2916-4DD6-B3CD-89F16148BFFC Q49787603-F16F3E07-32E3-406E-BEF9-4E65642A3C0C Q49968346-ECACD671-6055-4C26-918D-6CFFD8571703 Q50241406-98A4E43E-E11F-4624-A7AF-2C5C4E1C3A35 Q52880488-3DDDBE94-C5EC-4B10-AEAD-BD81D57DED1F Q53585290-69B8E369-ABD6-4896-A83F-B8C02D0DCC3E Q58706409-50D72910-E5DE-4A0A-8651-CE3C8017211E

P2860

Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial.

http://www.wikidata.org/entity/Q37022421

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 31 May 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Pramipexole in patients with e ...... andomised delayed-start trial.

@en

Pramipexole in patients with early Parkinson's disease

@nl

type

label

Pramipexole in patients with e ...... andomised delayed-start trial.

@en

Pramipexole in patients with early Parkinson's disease

@nl

prefLabel

Pramipexole in patients with e ...... andomised delayed-start trial.

@en

Pramipexole in patients with early Parkinson's disease

@nl

P1433

Q37022421-C992F2EB-E51E-4307-9658-9508A1FED5D1

P1476

Q37022421-92E1A97D-27D5-4B1B-BB7B-B6D207669B9D

P2093

Q37022421-2C1FDB69-5E89-42FD-A00F-1AB043ED3949

Q37022421-32228E1D-9BF3-40D0-A13A-AB429531CBC8

Q37022421-3B4DABC2-C25C-463C-817A-5A3AF197C04D

Q37022421-3EF510A7-6725-4726-BF2A-9EF50CF49311

Q37022421-5455D6EE-A084-4DD4-9FB8-7A2FA16C8798

Q37022421-C40CECFE-315B-439B-82BC-930A8F192811

P2860

Q37022421-11418290-5D44-42DE-9A22-502C26075C87

Q37022421-227C372E-69A7-41F0-BBE5-89EFFFC93198

Q37022421-252245F9-1E7D-48BB-9F87-F7E1C816260E

Q37022421-3C2A1ABE-F8D7-4D4E-92DC-2B6A843EAA75

Q37022421-44D31170-5DE9-47B3-B31F-AB0C7FDEE6E9

Q37022421-47BEFA2C-455D-4D26-BF28-0D13CC78B92F

Q37022421-488A68B5-A018-489C-9511-88847B29F5AE

Q37022421-6EDA2F94-B5FB-43AD-BDF7-6A2A790A1411

Q37022421-6FBDD820-AA2B-462D-B849-51C19C9AC8F4

Q37022421-7307255B-5B16-4398-923C-6C4E964C4417

P304

Q37022421-133019A9-3D8F-464E-9DFB-F31400B341EB

P31

Q37022421-26EE5498-101E-4066-B83D-71B6696D3D67

P356

Q37022421-D3D35406-5D0A-4B76-AD3E-E8CFD2789E9E

P433

Q37022421-BE1478FD-B5D5-48D7-A907-3C0E36E9055E

P478

Q37022421-D2352611-1BF7-4D3D-9C7E-0769FDE32C1E

P50

Q37022421-369D48F5-392E-4CB9-BED0-3D66D7D4B7F1

Q37022421-3E90735C-779D-4E17-8969-8D76C9FE80FE

Q37022421-62A2F0D3-5833-415F-9699-88AD65E85213

Q37022421-B429BD59-53D3-4CFA-910D-BF6ECA375A9E

Q37022421-EFF4DBD8-0963-41DE-8586-F5882DE7974D

P577

Q37022421-26561A34-A6D8-4CF6-957E-F3F05B1F4D39

P698

Q37022421-395288F4-878E-46C7-9980-9038D2EC54BB

P921

Q37022421-737D1B11-90AD-42F9-8635-8280464678A0

Q37022421-AAF5A294-D27C-4C12-9463-F8D6307A979F

P932

Q37022421-7EFC0725-FA43-4157-94F8-1A8692E2CD3E

P356

S1474-4422(13)70117-0

P1433

Lancet Neurology

P1476

Pramipexole in patients with e ...... andomised delayed-start trial.

@en

P2093

Cynthia L Comella

http://www.w3.org/2001/XMLSchema#string

Daniel H Massey

http://www.w3.org/2001/XMLSchema#string

Helen H Hsu

http://www.w3.org/2001/XMLSchema#string

Kenneth Marek

http://www.w3.org/2001/XMLSchema#string

Michael P McDermott

http://www.w3.org/2001/XMLSchema#string

Stefan Albrecht

http://www.w3.org/2001/XMLSchema#string

P2860

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

Parkinsonism: onset, progression and mortality

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease.

Levodopa and the progression of Parkinson's disease.

A double-blind, delayed-start trial of rasagiline in Parkinson's disease.

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.

Neuroprotection trials in Parkinson's disease: systematic review.

Timing of treatment initiation in Parkinson's disease: a need for reappraisal?

Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease.

Targets for neuroprotection in Parkinson's disease

P304

747-755

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1474-4422(13)70117-0

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Yoshikuni Mizuno

Anthony H V Schapira

P577

2013-05-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23726851

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3714436

http://www.w3.org/2001/XMLSchema#string